What is tumor mutational burden (TMB) and why is it tested

Understanding Tumor Mutational Burden (TMB)

What is TMB?

Tumor mutational burden (TMB) is a measure of how many mutations (genetic changes) are present in a cancer cell. Think of it this way: as cancer cells divide and grow, they accumulate mistakes in their DNA. TMB counts how many of these mutations exist per million base pairs of DNA sequenced—essentially measuring the "mutation load" in the tumor.

In practical terms: A tumor with high TMB has many mutations, while a tumor with low TMB has fewer mutations.

Why Do Doctors Test for TMB?

TMB has become an important test because of how it relates to immunotherapy response:

The Immune Connection

Mutations in cancer cells can create abnormal proteins that the immune system recognizes as "foreign." Tumors with high TMB have more of these abnormal proteins, which means the immune system has more targets to attack. This is why patients with high TMB often respond better to immunotherapy drugs (checkpoint inhibitors like pembrolizumab or nivolumab).

Clinical Decision-Making

According to NCCN Guidelines and ASCO recommendations, TMB testing helps oncologists:

• Predict immunotherapy response - High TMB suggests a patient may benefit from immune checkpoint inhibitors
• Guide treatment selection - TMB results help determine whether immunotherapy should be part of the treatment plan
• Identify patients who might benefit most - Particularly important in cancers like melanoma, non-small cell lung cancer, and others where immunotherapy is an option

How is TMB Measured?

TMB is typically calculated through next-generation sequencing (NGS) of tumor DNA. The test analyzes a panel of genes (usually 300-500 genes) and counts the total number of mutations found.

TMB Categories:

• High TMB: Generally ≥10 mutations per megabase (varies slightly by cancer type and testing platform)
• Low TMB: Below this threshold

Important Context

TMB is one piece of the puzzle. Your oncologist considers TMB alongside:

• Specific genetic mutations (like PD-L1 expression, BRAF, EGFR, etc.)
• Cancer type and stage
• Your overall health and treatment history
• Other biomarkers specific to your cancer

According to the American Cancer Society, while high TMB is generally associated with better immunotherapy response, it's not a perfect predictor—some patients with low TMB still respond well, and vice versa.

Questions to Ask Your Doctor

If TMB testing is being considered or has been done for you:

1. "What is my TMB score, and what does it mean for my specific cancer?"
2. "Does my TMB result change the treatment options you're recommending?"
3. "Are there other biomarkers you're looking at alongside TMB to guide treatment?"
4. "If my TMB is high, does that mean immunotherapy is the best option for me?"
5. "How reliable is TMB testing for predicting response in my type of cancer?"

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.